🚀 VC round data is live in beta, check it out!
NRGene Valuation Multiples
Discover revenue and EBITDA valuation multiples for NRGene and similar public comparables like Ayfie International, XIAO-I, VSee Health, Biovica International and more.
NRGene Overview
About NRGene
NRGene Technologies Ltd is engaged in the development of artificial intelligence-based software for the analysis of genetic information in order to improve species of plants and animals.
Founded
N/A
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$6M
NRGene Financials
NRGene reported last fiscal year revenue of $3M and negative EBITDA of ($965K).
In the same fiscal year, NRGene generated $2M in gross profit, ($965K) in EBITDA losses, and had net loss of ($2M).
NRGene P&L
In the most recent fiscal year, NRGene reported revenue of $3M and EBITDA of ($965K).
NRGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $2M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 61% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($965K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (30%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (50%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (47%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NRGene Stock Performance
NRGene has current market cap of $12M, and enterprise value of $6M.
Market Cap Evolution
NRGene's stock price is $0.87.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6M | $12M | 0.0% | XXX | XXX | XXX | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNRGene Valuation Multiples
NRGene trades at 2.0x EV/Revenue multiple, and (6.6x) EV/EBITDA.
NRGene Financial Valuation Multiples
As of April 19, 2026, NRGene has market cap of $12M and EV of $6M.
Equity research analysts estimate NRGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NRGene has a P/E ratio of (7.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (6.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (4.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.3x | XXX | XXX | XXX |
| P/E | — | XXX | (7.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 88.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NRGene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NRGene Margins & Growth Rates
NRGene's revenue in the last fiscal year grew by 146%.
NRGene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 146% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (30%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (64%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 20% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 42% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 110% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NRGene Public Comps
See public comps and valuation multiples for other Artificial Intelligence and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NRGene | XXX | XXX | XXX | XXX | XXX | XXX |
| Ayfie International | XXX | XXX | XXX | XXX | XXX | XXX |
| XIAO-I | XXX | XXX | XXX | XXX | XXX | XXX |
| VSee Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Biovica International | XXX | XXX | XXX | XXX | XXX | XXX |
| Glycorex Transplantation | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NRGene M&A Activity
NRGene acquired XXX companies to date.
Last acquisition by NRGene was on XXXXXXXX, XXXXX. NRGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NRGene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNRGene Investment Activity
NRGene invested in XXX companies to date.
NRGene made its latest investment on XXXXXXXX, XXXXX. NRGene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NRGene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NRGene
| Where is NRGene headquartered? | NRGene is headquartered in Israel. |
| Is NRGene publicly listed? | Yes, NRGene is a public company listed on Tel Aviv Stock Exchange. |
| What is the stock symbol of NRGene? | NRGene trades under NRGN ticker. |
| When did NRGene go public? | NRGene went public in 2021. |
| Who are competitors of NRGene? | NRGene main competitors are Ayfie International, XIAO-I, VSee Health, Biovica International. |
| What is the current market cap of NRGene? | NRGene's current market cap is $12M. |
| What is the current revenue of NRGene? | NRGene's last fiscal year revenue is $3M. |
| What is the current EV/Revenue multiple of NRGene? | Current revenue multiple of NRGene is 2.0x. |
| Is NRGene profitable? | No, NRGene is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.